RecruitingPhase 2NCT07126236
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- Principal Investigator
- Mariana Bastos-OreiroHospital General Universitario Gregorio Marañón
- Intervention
- Epcoritamab(drug)
- Enrollment
- 80 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2031
Study locations (15)
- Hospital Universitario Miguel Servet, Zaragoza, Aragon, Spain
- Hospital Universitario de Burgos, Burgos, Castille and León, Spain
- ICO Badalona, Badalona, Catalonia, Spain
- Hospital Universitari Vall d'Hebrón, Barcelona, Catalonia, Spain
- Hospital San Pedro de Alcántara, Cáceres, Extremadura, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
- Hospital Universitario Infanta Leonor, Madrid, Madrid, Spain
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Madrid, Spain
- Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
- Hospital Universitario Costa del Sol, Marbella, Málaga, Spain
- Hospital Universitario Central de Asturias, Oviedo, Principality of Asturias, Spain
- Hospital Universitario de Canarias, San Cristóbal de La Laguna, Tenerife, Spain
- Hospital Universitario Dr. Peset, Valencia, Valencia, Spain
- Hospital Universitario y Politécnico La Fe, Valencia, Valencia, Spain
- Hospital Universitario de Basurto, Bilbao, Vizcaya, Spain
Collaborators
AbbVie · Incyte Corporation · Evidenze Health España (CRO)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07126236 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.